Danaher Corporation (DHR) Maintains Buy Rating as Analysts See Upside in 2026

We recently compiled a list of the 10 Best Investments During A Recession. Danaher Corporation is placed third among the best investments.

TheFly reported on January 7 that TD Cowen raised its price target on DHR to $270 from $260, maintaining a Buy rating. The adjustment was part of the firm’s Q4 outlook for the life sciences tools sector. Even though recent share gains have raised expectations, analysts pointed out that some companies have already offered conservative 2026 outlooks, indicating possible upside for DHR. The business is well-positioned to profit from the industry’s continued strength and development prospects in the upcoming year, according to TD Cowen.

Separately, on January 12, the company provided a favorable operational update during the J.P. Morgan Healthcare Conference. Danaher Corporation (NYSE:DHR) stated that it now expects its adjusted diluted net earnings per share (EPS) to be between $7.70 and $7.80 for the full year 2025. Additionally, the company projected a mid-single-digit percent growth in sales over the previous year for the fourth quarter.

Danaher Corporation (NYSE:DHR) operates as a global science and technology innovator. Following its strategic shift to focus exclusively on Life Sciences and Diagnostics, the business provides sophisticated tools and services that improve patient health and accelerate the development of life-changing therapies.

While we acknowledge the potential of DHR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 12 Best Multibagger Stocks to Buy Heading into 2026 and 7 Best Rising Tech Stocks to Buy Now.

Disclosure: None.